c-FLIPp43 induces activation of the nuclear factor‑κB signaling pathway in a dose-dependent manner in the A375 melanoma cell line

Wang,Yujue; Tu,Yating; Lu,Jiejie; Tao,Juan; Li,Yan

doi:10.3892/mmr.2014.2364

c-FLIPp43 induces activation of the nuclear factor‑κB signaling pathway in a dose-dependent manner in the A375 melanoma cell line

Authors:
- Yujue Wang
- Yating Tu
- Jiejie Lu
- Juan Tao
- Yan Li
View Affiliations

Affiliations: Department of Dermatology, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Dermatology and Venereology, Hainan Provincial Center for Skin Disease and STD Control, Haikou, Hainan 570206, P.R. China
Published online on: July 7, 2014 https://doi.org/10.3892/mmr.2014.2364
Pages: 1438-1442

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to investigate the role of c‑FLIPp43 in the regulation of the nuclear factor (NF)‑κB signaling pathway in melanoma cell lines, a eukaryotic expression vector for c‑FLIPp43 was constructed with the pCMV‑Tag2B plasmid. The monoclonal A375 cells with stable expression of c‑FLIPp43 were obtained by G418 selection and were identified with western blot analysis. The protein level of NF‑κBp65 in the A375 cell line with stable expression of c‑FLIPp43 was examined by western blot analysis. The translocation of NF‑κBp65 was examined using immunofluorescence. The A375 cell lines were transfected with the pCMV‑Tag2B‑cFLIPp43 vector at different doses and the activation of the NF‑κB signaling pathway was examined by the dual‑luciferase reporter assay system. The stable expression of c‑FLIPp43 in the A375 cell lines transfected with the pCMV‑Tag2B‑cFLIPp43 vector increased the protein level of NF‑κBp65 compared with in the A375 cell lines transfected with the empty vector. Transfection of the cells using the pCMV‑Tag2B‑cFLIPp43 vector increased the amount of NF‑κBp65 in the nucleus in a dose‑dependent manner. In conclusion, the transfection of the c‑FLIPp43 expression vector induces the protein expression of NF‑κBp65 and promotes the activation of the NF‑κB signaling pathway in the A375 melanoma cell line.

View Figures

View References

1	Markovic SN, Erickson LA, Rao RD, et al: Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clinic Proc. 82:364–380. 2007. View Article : Google Scholar : PubMed/NCBI
2	Igney FH and Krammer PH: Death and anti-death: tumour resistance to apoptosis. Nature Rev Cancer. 2:277–288. 2002. View Article : Google Scholar : PubMed/NCBI
3	Kataoka T, Schröter M, Hahne M, et al: FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol. 161:3936–3942. 1998.
4	Irmler M, Thome M, Hahne M, et al: Inhibition of death receptor signals by cellular FLIP. Nature. 388:190–195. 1997. View Article : Google Scholar : PubMed/NCBI
5	Bullani RR, Huard B, Viard-Leveugle I, et al: Selective expression of FLIP in malignant melanocytic skin lesions. J Invest Dermatol. 117:360–364. 2001. View Article : Google Scholar : PubMed/NCBI
6	Tian F, Lu JJ, Wang L, et al: Expression of c-FLIP in malignant melanoma, and its relationship with the clinicopathological features of the disease. Clin Exp Dermatol. 37:259–265. 2012. View Article : Google Scholar : PubMed/NCBI
7	Kataoka T and Tschopp J: N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway. Mol Cell Biol. 24:2627–2636. 2004. View Article : Google Scholar : PubMed/NCBI
8	Dohrman A, Kataoka T, Cuenin S, et al: Cellular FLIP (long form) regulates CD8⁺ T cell activation through caspase-8-dependent NF-kappa B activation. J Immunol. 174:5270–5278. 2005.PubMed/NCBI
9	Aggarwal BB: Nuclear factor-kappa B: the enemy within. Cancer Cell. 6:203–208. 2004.
10	McNulty SE, del Rosario R, Cen D, Meyskens FL Jr and Yang S: Comparative expression of NFkappaB proteins in melanocytes of normal skin vs. benign intradermal naevus and human metastatic melanoma biopsies. Pigment Cell Res. 17:173–180. 2004. View Article : Google Scholar
11	Thu YM, Su Y, Yang J, et al: NF-kappaB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathway. Oncogene. 31:2580–2592. 2012.PubMed/NCBI
12	Griffith TS, Chin WA, Jackson GC, Lynch DH and Kubin MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol. 161:2833–2840. 1998.PubMed/NCBI
13	Lee SH, Kim HS, Kim SY, et al: Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer. APMIS. 111:309–314. 2003. View Article : Google Scholar : PubMed/NCBI
14	Nam SY, Jung GA, Hur GC, et al: Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Science. 94:1066–1073. 2003. View Article : Google Scholar : PubMed/NCBI
15	Zhou XD, Yu JP, Liu J, et al: Overexpression of cellular FLICE-inhibitory protein (FLIP) in gastric adenocarcinoma. Clin Sci (Lond). 106:397–405. 2004. View Article : Google Scholar : PubMed/NCBI
16	Wilson NS, Dixit V and Ashkenazi A: Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol. 10:348–355. 2009. View Article : Google Scholar : PubMed/NCBI
17	Okano H, Shiraki K, Inoue H, et al: Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest. 83:1033–1043. 2003. View Article : Google Scholar : PubMed/NCBI
18	Elnemr A, Ohta T, Yachie A, et al: Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int J Oncol. 18:311–316. 2001.
19	Xiao CW, Yan X, Li Y, Reddy SA and Tsang BK: Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein. Endocrinology. 144:623–630. 2003. View Article : Google Scholar
20	Zhang X, Jin TG, Yang H, et al: Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res. 64:7086–7091. 2004. View Article : Google Scholar
21	Olsson A, Diaz T, Aguilar-Santelises M, et al: Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia. 15:1868–1877. 2001. View Article : Google Scholar : PubMed/NCBI
22	MacFarlane M, Harper N, Snowden RT, et al: Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene. 21:6809–6818. 2002. View Article : Google Scholar : PubMed/NCBI
23	Korkolopoulou P, Goudopoulou A, Voutsinas G, et al: c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology. 63:1198–1204. 2004. View Article : Google Scholar
24	Djerbi M, Screpanti V, Catrina AI, et al: The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med. 190:1025–1032. 1999. View Article : Google Scholar : PubMed/NCBI
25	Ullenhag GJ, Mukherjee A, Watson NF, et al: Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res. 13:5070–5075. 2007. View Article : Google Scholar : PubMed/NCBI
26	Wang W, Wang S, Song X, et al: The relationship between c-FLIP expression and human papillomavirus E2 gene disruption in cervical carcinogenesis. Gynecol Oncol. 105:571–577. 2007. View Article : Google Scholar : PubMed/NCBI
27	Valnet-Rabier MB, Challier B, Thiebault S, et al: c-Flip protein expression in Burkitt’s lymphomas is associated with a poor clinical outcome. Br J Haematol. 128:767–773. 2005.
28	Valente G, Manfroi F, Peracchio C, et al: cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy. Br J Haematol. 132:560–570. 2006. View Article : Google Scholar : PubMed/NCBI
29	Zeise E, Weichenthal M, Schwarz T and Kulms D: Resistance of human melanoma cells against the death ligand TRAIL is reversed by ultraviolet-B radiation via downregulation of FLIP. J Invest Dermatol. 123:746–754. 2004. View Article : Google Scholar : PubMed/NCBI
30	Ricci MS, Jin Z, Dews M, et al: Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol. 24:8541–8555. 2004. View Article : Google Scholar : PubMed/NCBI
31	Li W, Zhang X and Olumi AF: MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res. 67:2247–2255. 2007. View Article : Google Scholar : PubMed/NCBI
32	Kreuz S, Siegmund D, Rumpf JJ, et al: NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J Cell Biol. 166:369–380. 2004. View Article : Google Scholar : PubMed/NCBI
33	Neumann L, Pforr C, Beaudouin J, et al: Dynamics within the CD95 death-inducing signaling complex decide life and death of cells. Mol Syst Biol. 6:3522010. View Article : Google Scholar : PubMed/NCBI
34	Hu WH, Johnson H and Shu HB: Activation of NF-kappaB by FADD, Casper, and caspase-8. J Biol Chem. 275:10838–10844. 2000. View Article : Google Scholar : PubMed/NCBI
35	Oztürk S, Schleich K and Lavrik IN: Cellular FLICE-like inhibitory proteins (c-FLIPs): fine-tuners of life and death decisions. Exp Cell Res. 318:1324–1331. 2012.PubMed/NCBI
36	Amiri KI and Richmond A: Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev. 24:301–313. 2005. View Article : Google Scholar : PubMed/NCBI
37	Mayo MW and Baldwin AS: The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta. 1470:M55–M62. 2000.PubMed/NCBI
38	Huang S, DeGuzman A, Bucana CD and Fidler IJ: Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res. 6:2573–2581. 2000.PubMed/NCBI
39	Galligan L, Longley DB, McEwan M, et al: Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther. 4:2026–2036. 2005. View Article : Google Scholar : PubMed/NCBI